A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.
This study has been completed.
Study NCT00001100
Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received: November 2, 1999
Last Updated: November 11, 2005
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
